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ORIGINAL ARTICLE
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Abstract
Italian participants in the European REVIVE survey reported that vaginal and vulvar atrophy
(VVA) impaired various aspects of their lives, notably the ability to enjoy sex. The aim of the
present study was to explore regional differences in knowledge, experiences, and treatment of
VVA in the Italian REVIVE sample (n¼ 1000), which was analyzed according to region of
residence. While many respondents were unfamiliar with the VVA condition, most could relate
their VVA symptoms to the menopause. The rate of diagnosis of VVA was twice as high in
Central Italy as in the North-East. For individual VVA symptoms, 25.4–41.6% of respondents
judged that the symptom had worsened over time. There were no significant regional
differences for symptoms in terms of reported rate, change in severity, impact on sexual
activity, or health-care visits. Testosterone cream and OTC medication based on hyaluronic acid
showed significant regional differences in lifetime rates of use. In Italy, there are modest
regional differences in knowledge, diagnosis, and treatment of VVA, some of which may be
explained by inter-regional differences in health care. Further efforts are needed to ensure that
Italian women are properly informed about VVA and have access to appropriate health care
and treatments.
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Introduction
Vulvar and vaginal atrophy (VVA) is a chronic condition
associated with the dramatic reduction in estrogen levels at the
menopause, which is now part of the genitourinary syndrome of
menopause [1]. It is characterized by vaginal dryness and itching,
pain during sexual intercourse, urinary urgency and urge incon-
tinence, symptoms which can worsen over time [2,3]. While it is
hard to accurately estimate the prevalence of VVA, US and
European survey data from the last 10 years gave figures ranging
from 38 to 54% [4–6]. These and other data confirm that VVA
remains a major public health problem.
VVA has a considerable negative impact on quality of life (QoL)
[6,7]. In Women’s Voices in the Menopause, an international survey
of women aged 55–65, 40% of respondents reported that vaginal
discomfort had worsened their sex life [8]. It had also negatively
affected their self-esteem (17%), marriage/relationship (13%), and
social life (7%). In a second international survey of postmenopausal
women – Vaginal Health: Insights, Views & Attitudes (VIVA) –
three-quarters of respondents expressed a negative effect of VVA on
QoL [9]. Impairment of sleep or of general enjoyment of life was
reported by just under a quarter of respondents in REal women’s
VIews of treatment options for menopausal Vaginal changEs
(REVIVE), a large US survey [5].
When the US REVIVE survey was replicated in Europe
(Italy, Germany, Spain, and the UK), over two-thirds of the
women who had ever had VVA reported a negative effect on
their sex life [2]. In spite of this, only 45% of respondents were
receiving treatment at the time of the survey, and many
expressed dissatisfaction with VVA treatments. Indeed, VVA is
under-treated for a number of reasons, including embarrassment
at seeking professional medical help and safety concerns over
the long-term use of estrogen [8,10,11], which is effective at
relieving VVA symptoms [12].
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The European REVIVE study [2] and other international
studies [8,9,13,14] reveal cultural differences in the impact
of VVA on female sexuality and relationships. A recent
European interview- and survey-based study further identified
personality traits as an important factor influencing women’s
attitudes and behavior regarding VVA [15]. Nonetheless, the
global picture is one of widespread discomfort and unre-
lieved suffering.
A recent analysis of the REVIVE data from Italy found
that VVA reduced enjoyment of sex in 75% of respondents
[3]. A majority of the respondents had expected their
physician to initiate a discussion about sexual health after
the menopause, but this rarely happened. For this reason,
perhaps, less than 10% of the women currently receiving
treatment were using a prescription medication; the vast
majority were using over-the-counter (OTC) medications [3].
The AGATA Study also refers to Italian postmenopausal
women, finding that almost 30% had had a previous
diagnosis of VVA and were treated either with no therapy
(10%), systemic hormone (9%), local hormone (45%), or
local non-hormonal (37%) therapy [16].
The objective of the present analysis was to explore regional
differences in experiences of VVA among Italian women included
in the European REVIVE survey.
Methods
Conducted in 2014, the European REVIVE survey [2] used the
same methodology as the original US REVIVE survey [5].
Briefly, women aged 45–75 years and living in Italy, Germany,
Spain, or the UK were screened for eligibility based on cessation
of menstruation, menopause, and lifetime history of VVA
symptoms. An invitation to participate has been sent to
postmenopausal women with current or previous VVA.
Participants completed an online questionnaire that lasted
approximately 35 min. The questionnaire, which had been
translated from the US REVIVE questionnaire and adapted
culturally, was accessed via a secure online portal. To ensure that
the questions could be fully understood, it was initially tested in a
subsample of 50 participants.
The survey was approved by the relevant independent Ethics
Committees, and all participants provided informed consent. As
remuneration for their participation, participants received points
that could be exchanged for vouchers or gadgets, but not money.
Participants provided information on the following: knowledge
about VVA and menopausal symptoms, interactions with health-
care providers (HCPs) regarding VVA symptoms, impact of VVA
symptoms on sex life and activities of daily living, lifetime and
current use of different treatments for VVA, and attitudes toward
VVA treatments. Those who fulfilled all the screening criteria and
who had valid data for the analyzed variables were considered
eligible.
European REVIVE data for Italy alone were used in the
present study. In total, 7284 of the 32 384 women who were
screened and 1000 of the 3768 eligible participants were from
Italy [3]. The Italian sample covers all regions of Italy in a
demographically balanced manner: North-East (19.0% of the
sample), North-West (33.8%), Central (20.9%), South (18.0%),
and Islands (8.3%). The REVIVE study variables were
analyzed according to geographical region.
Descriptive statistics were calculated without imputation
of missing values. Relative frequency distributions are
presented for categorical variables. Pearson’s chi-squared
tests with a 0.05 significance level were performed to
detect differences by region in the frequencies of the
survey responses.
Results
Demographics
Baseline demographics of the 1000 European REVIVE partici-
pants from Italy are presented elsewhere [3]. Briefly, nearly two-
thirds of the participants were aged 51–60 years; none of them
had menstruated in the previous 12 months. Most participants
(79%) had received previous treatment for VVA, and 58% were
receiving treatment at the time of the survey. Notably, there were
regional differences in age distributions (p¼ 0.029, Pearson’s chi-
squared test), with higher proportions of participants aged
71 + years in North-East (4.7%) and South Italy (3.3%) compared
to other regions (0.5–1.2%) (Table 1). Marital status, occupational
status, education, number of children, and having children living
at home also showed significant regional differences (p50.05).
Awareness of VVA and its causes
Overall, 415 of the 1000 participants reported being not at all
familiar with VVA as a condition, with the proportion ranging
from 40.0% in the South to 42.6% in Central Italy; 5.4% of
participants reported being extremely familiar with VVA (range
3.3% [Central] to 7.2 [Islands]). In spite of this regional variation,
Pearson’s chi-squared test results indicated no significant differ-
ences (p¼ 0.254). Over half of the participants specifically
mentioned the menopause when asked what they believed to be
the cause of their VVA symptoms.
VVA symptoms
The commonest VVA symptom experienced by the Italian
REVIVE participants was vaginal/vulvar dryness, with an overall
rate of 77.7% (range 69.9% [Islands] to 81.8% [Central])
(Figure 1A). In fact, vaginal/vulvar dryness was the most
frequently reported menopausal symptom, ahead of hot flushes
(75.1%), night sweats (61.4%), and weight gain (60.0%).
However, there were no significant regional differences in
vaginal/vulvar dryness rate (p¼ 0.108, Pearson’s chi-squared
test). Pain during intercourse (30.5%) and vaginal/vulvar irritation
(29.5%) were also frequently reported, although rates of these
VVA symptoms did not differ significantly between different
geographical regions (p¼ 0.251 for pain during intercourse and
p¼ 0.240 for vaginal/vulvar irritation). Vaginal/vulvar pain/sore-
ness was reported less frequently (8.2%) and showed no
significant regional variation (p¼ 0.499).
Generally, participants found their VVA symptoms very
bothersome. The following proportions of participants reported
their symptoms as ‘‘extremely bothersome’’: vaginal/vulvar
dryness, 33.5%; pain during intercourse, 59.0%; vaginal/vulvar
irritation, 45.1%; and vaginal/vulvar pain/soreness, 42.7%. While
the proportion of sufferers describing their vaginal/vulvar pain/
soreness as extremely bothersome varied between 35.7% (North-
East and South) and 60.0% (Islands), there were no significant
regional differences in how bothersome the participants found any
of their VVA symptoms (p40.05).
Interestingly, reported rates of VVA diagnosis showed signifi-
cant regional variation (p¼ 0.003), ranging from 13.7% in the
North-East to 29.7% in Central Italy (Figure 1B).
Participants were asked about the severity of their VVA
symptoms at the time of the survey compared to when the
symptoms first arose. Of the 777 participants who reported
vaginal/vulvar dryness, 211 (27.2%) felt that it had worsened.
There were no regional differences (p¼ 0.757). Pain during
intercourse had worsened in 127/305 participants (41.6%),
vaginal/vulvar irritation in 75/295 participants (25.4%) and
vaginal/vulvar pain/soreness in 29/82 participants (35.4%).
There were no significant geographical differences (p40.05).
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Participants were further asked which of their VVA and other
menopausal symptoms they believed were a direct cause of the
menopause. Of the 1000 participants, 733 attributed hot flushes to
the menopause and 678 attributed vaginal/vulvar dryness to it. For
vaginal/vulvar dryness, the rate ranged from 55.4% (Islands) to
76.1% (Central) (p¼ 0.003) (Figure 2). Significant regional
differences were also observed for depression (range 26.8%
[Central] to 45.8% [Islands], p¼ 0.018) and breast pain/tender-
ness (range 3.0% [North-West] to 10.0% [South], p¼ 0.006).
Impact of VVA on sexual activity and other aspects of life
VVA negatively affected the sex lives of the Italian REVIVE
participants. Notably, vaginal/vulvar dryness had affected sexual
activity in the previous 12 months in just over half (50.6%) of the
1000 participants. Pain during intercourse had affected sexual
activity in the previous 12 months in 20.5% of participants and
vaginal/vulvar irritation had affected it in 15.6% of participants.
For the effects of different VVA symptoms on sexual activity,
there were no significant differences between different geograph-
ical regions (p¼ 0.258, Pearson’s chi-squared test). Importantly,
two-fifths of the participants (n¼ 397) did not agree that they
could live with the loss of intimacy caused by their VVA
symptoms, while VVA symptoms prevented 52.1% of participants
from being as sexually spontaneous as they would like. There
were no regional differences for loss of intimacy (p¼ 0.391) or
sexual spontaneity (p¼ 0.148). Over one-third of participants
(37.3%) reported making excuses not to have sex because of their
VVA symptoms, with no regional differences (p¼ 0.724).
VVA symptoms also affected other aspects of the participants’
lives, interfering with sleep in 30.3% of participants, the
relationship with their partner in 66.0% of participants, and
enjoyment of life in general in 40.7% of participants. There were
no significant regional differences (p40.05).
Health care for VVA
Participants were asked how many times during the previous 12 months
they had visited their primary HCP for gynecological reasons.
Of the 961 participants who answered this question, 276 (28.7%)
had made no such visits to HCP; 457 (47.6%) had made one visit
and 147 (15.3%) two visits. Only 81 of the respondents (8.4%) had
made three or more visits to their HCP for gynecological reasons.
While there was some evidence of regional variation – 24.0% of
respondents in the South had made no visits compared to 32.1%
for the Islands, 13.1% of participants in Central Italy had made
three or more visits versus 4.9% in the North-East – overall there
were no significant geographical differences (p¼ 0.063, Pearson’s
chi-squared test).
When asked whether they had ever discussed any of their VVA
symptoms with a HCP, two-thirds of the participants (n¼ 666)
reported that they had done so; 219 had never done so and 115
could not remember or were unsure. While there was modest
regional variation in the proportion of participants who had never
discussed their VVA symptoms with a HCP (range 18.3% [North-
West] to 27.2% [South]), there were no significant differences
(p¼ 0.341). The participants who had discussed their VVA
Table 1. Baseline demographic data for the Italian REVIVE participants.
North-West North-East Central South Islands All regions Pearson
Age (years), n (%) p¼ 0.029*
45–50 30 (8.9) 24 (12.6) 20 (9.6) 15 (8.3) 10 (12.0) 99 (9.9)
51–55 113 (33.4) 59 (31.1) 59 (28.2) 67 (37.2) 27 (32.5) 325 (32.5)
56–60 99 (29.3) 47 (24.7) 85 (40.7) 53 (29.4) 25 (30.1) 309 (30.9)
61–65 76 (22.5) 36 (18.9) 32 (15.3) 28 (15.6) 14 (16.9) 186 (18.6)
66–70 16 (4.7) 15 (7.9) 12 (5.7) 11 (6.1) 6 (7.2) 60 (6.0)
71–75 4 (1.2) 9 (4.7) 1 (0.5) 6 (3.3) 1 (1.2) 21 (2.1)
Marital status, n (%) p¼ 0.038*
Married 213 (63.0) 125 (65.8) 137 (65.6) 132 (73.3) 66 (79.5) 673 (67.3)
Cohabiting 30 (8.9) 17 (8.9) 10 (4.8) 12 (6.7) 2 (2.4) 71 (7.1)
Separated 12 (3.6) 10 (5.3) 8 (3.8) 7 (3.9) 3 (3.6) 40 (4.0)
Divorced 32 (9.5) 13 (6.8) 26 (12.4) 8 (4.4) 6 (7.2) 85 (8.5)
Single 33 (9.8) 17 (8.9) 20 (9.6) 8 (4.4) 1 (1.2) 79 (7.9)
Widowed 18 (5.3) 8 (4.2) 8 (3.8) 13 (7.2) 5 (6.0) 52 (5.2)
Occupational status, n (%) p50.001*
Employed 118 (34.9) 71 (37.4) 82 (39.2) 45 (25.0) 26 (31.3) 342 (34.2)
Self-employed 36 (10.7) 14 (7.4) 20 (9.6) 12 (6.7) 6 (7.2) 88 (9.6)
Housewife 78 (23.1) 41 (21.6) 57 (27.3) 73 (40.6) 29 (34.9) 278 (27.8)
Unemployed 34 (10.1) 14 (7.4) 25 (12.0) 25 (13.9) 10 (12.0) 108 (10.8)
Unable to work 2 (0.6) 0 1 (0.5) 1 (0.6) 0 4 (0.4)
Retired 70 (20.7) 50 (26.3) 24 (11.5) 24 (13.3) 12 (14.5) 180 (18.0)
Education, n (%) p¼ 0.001*
No formal education 1 (0.3) 3 (1.6) 3 (1.4) 0 (0.0) 2 (2.4) 9 (0.9)
Bachelor’s degree or higher 55 (16.3) 34 (17.9) 45 (21.5) 40 (22.2) 18 (21.7) 192 (19.2)
Other 282 (83.4) 153 (80.5) 161 (77.0) 140 (77.8) 63 (75.9) 799 (79.9)
Number of children, n (%) p50.001*
0 75 (22.2) 35 (18.4) 45 (21.5) 22 (12.2) 9 (10.8) 186 (18.6)
1 118 (34.9) 63 (33.2) 54 (25.8) 38 (21.1) 14 (16.9) 287 (28.7)
2 110 (32.5) 66 (34.7) 85 (40.7) 83 (46.1) 42 (50.6) 386 (38.6)
3 30 (8.9) 20 (10.5) 16 (7.7) 31 (17.2) 13 (15.7) 110 (11.0)
4+ 5 (1.5) 6 (3.2) 9 (4.3) 6 (3.3) 5 (6.0) 31 (3.1)
Children living at home, n (%) p¼ 0.001*
0 174 (51.5) 98 (51.6) 92 (44.0) 62 (34.4) 30 (36.1) 456 (45.6)
1+ 164 (48.5) 92 (48.4) 117 (56.0) 118 (65.6) 53 (63.9) 544 (54.4)
Total 338 190 209 180 83 1000
Percentages denote the proportion of participants in each category for that particular geographical region.
*p50.05.
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symptoms with a HCP were asked who had initiated the first
discussion. Of the 665 participants who answered this question,
563 (84.7%) had initiated the discussion themselves – either
during a checkup or by specifically booking an appointment to
discuss their symptoms. There were no significant regional
differences (p¼ 0.136).
VVA treatments
Participants were asked to indicate which treatments they had
ever used for their VVA symptoms. The two most frequently used
products were both OTC medications: a product range based
partly on hyaluronic acid (used at some point by 50.5% of
participants) and a plant extract-based cream (23.8%).
There were significant geographical differences in lifetime use
of VVA treatments (p¼ 0.003, Pearson’s chi-squared test).
Notably, one particular OTC medication based on hyaluronic
acid was more frequently used on the Islands (9.6%) than in other
regions (1.4 to 2.2%) (p50.001). Prescription medications based
on testosterone cream compounded at pharmacies were more
frequently used in North-East Italy (2.1%) compared to other
regions (0.0 to 0.6%) (p¼ 0.011), although few participants were
using testosterone. Geographical differences for other VVA
treatments were not statistically significant.
There were no overall geographical differences in current use
of different VVA treatments (p¼ 0.208). The above-mentioned
OTC product range was the treatment that was currently being
used by the highest number of participants (n¼ 264).
A total of 698 participants reported having ever used one or
more of 11 listed OTC medications for VVA, with the proportion
varying from 63.6% in Central Italy to 74.2 in the North-East.
Reported use of natural products ranged from 7.1% in the North-
West to 8.9% in the North-East. Prescription medications for VVA
(estrogen and testosterone) showed more marked regional trends,
Figure 1. VVA symptoms and diagnoses by
geographical region. A: Proportions of par-
ticipants reporting individual VVA symptoms
after the menopause. B: Proportions of par-
ticipants ever diagnosed with VVA. p values
is for Pearson’s chi-squared test.
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Figure 2. Proportions of women attributing
their VVA symptoms to the menopause by
geographical region. p values is for Pearson’s
chi-squared test.
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with 10.5% of women in Central Italy having used them compared
to 5.0% in the South. Very few women had ever used a medical
device to treat their VVA symptoms.
Current use of VVA treatments mirrored lifetime use. OTC
medications (range 40.2% in Central Italy to 51.6% in the North-
East) were more commonly used than other treatments. Current
use of natural products (2.4% in Central Italy and on the Islands to
5.3% in the North-East) and prescription medications (1.2% on the
Islands to 5.7% in Central Italy) showed evidence of regional
variation. Only one woman was currently using testosterone and
none were using a medical device.
Discussion
This analysis of Italian data from the wider European REVIVE
study reveals regional differences in VVA symptoms and their
treatment. Notably, the rate of VVA diagnosis was higher in Central
Italy than in the North-East. The proportion of participants who
had made three or more health-care visits for gynecological reasons
in the previous 12 months was more than twice as high in Central
versus North-East Italy (13.1% versus 4.9%). However, the
difference in VVA diagnosis rate did not reflect a significant
difference between these two regions in either number of health-
care visits or likelihood of having discussed VVA symptoms with a
HCP. A recent analysis of data for the year 2006 from an annual
international survey – European Union Statistics on Income and
Living Conditions (EU-SILC) – found that unmet medical needs
due to unavailability of health care (long waiting lists) were more
frequent in Central Italy (25.1%) compared to the North-East
(16.7%) [17]. This suggests that the higher rate of VVA diagnosis in
Central versus North-East Italy in the present study is not due to a
difference in health-care availability.
The proportion of participants who had never discussed their
VVA symptoms with a HCP was highest in the South of Italy.
While an exploration of reasons why participants had not
discussed their VVA symptoms with a HCP revealed no
significant regional differences (data not shown), there is
evidence that health care is inferior in terms of quality or
coverage in South Italy compared to other regions of the country
[18]. According to the 2006 EU-SILC data [17], the proportion of
adults with unmet medical needs was higher in the South (10.6%)
than in the North-East (4.6%) and North-West (4.9%). Per capita
health-care expenditure is generally higher in the North than in
Central Italy and the South [19], and survey data from 1993 and
2005 suggest that the perceived quality of public health services is
lower in the South than in Central Italy and the North [20]. This is
in spite of (or perhaps a contributor to) higher rates of obesity,
sedentary behavior, and hospitalization in the South than in other
parts of Italy [16,18]. Deficiencies in health care in the South have
been attributed mainly to cultural factors [17,20]. One or more of
these cultural elements may explain the relatively high proportion
of women in South Italy who had never discussed their VVA
symptoms with a HCP [21]. Additionally, we cannot exclude
specific socio-cultural attitudes of both women and HCPs toward
discussing intimate topics [22], which could be related with a
higher ratio of male gynecologists in the South.
There were regional differences in the percentages of partici-
pants attributing vaginal/vulvar dryness and other menopausal
symptoms to the menopause. A plausible explanation for these
differences is regional differences in health education or the
provision of information about the menopause. Previous studies of
knowledge of the menopause among Italian women did not
specifically examine the role of geography [16,23,24].
Observed geographical differences in the use of certain
medications may be explained by a number of factors. Starting
in the 1970s and gathering pace since the 1990s, Italian health
care has undergone a process of decentralization, which has
contributed to considerable regional differences in the use of
certain medications [25]. Moreover, there is evidence of regional
differences in the public funding of medications in favor of poorer
regions such as those in the South [26]. In spite of this, reported
use of prescription medications in the present study was actually
lower in women in Southern Italy than in women living in other
regions of the country.
Some of the findings in the present study may be attributed to
previously documented socio-cultural differences between north-
ern and southern regions of Italy [27]. Others may be partly
explained by the observed inter-regional differences in demo-
graphics: age, marital status, occupational status, education,
number of children, and having children living at home. Marital
status, occupational status, and education were previously
identified as key predictors of self-rated health in the Italian
population [19]. In the context of VVA, age in particular may be
important, given that 25.4–41.6% of Italian REVIVE participants
reported that their symptoms were worse at the time of the survey
compared to when they first arose.
The current study has limitations and strengths. The present
findings may have been affected by the biases that typically affect
surveys, such as recall bias and response bias. Also, multiple
statistical comparisons were conducted without multiple testing
correction, which means that some of the significant findings are
potentially a result of chance. Moreover, because the study
explored differences between five geographical regions in one of
the four countries included in the European REVIVE study,
numbers of participants were modest compared to the overall
European REVIVE sample (n¼ 3768). Nonetheless, the geo-
graphical subgroups were representative of the population distri-
bution of Italy. Additionally, this is a nation-wide multicenter
research that investigates VVA among women eventually attend-
ing gynecological services and that depicts a real-world situation
of the Italian clinical practice. Moreover, the survey questionnaire
was initially tested in a subset of participants to make sure that the
questions could be understood.
Conclusions
The present analyses reveal modest differences in knowledge,
diagnosis, and treatment of VVA between different Italian
regions. Published literature on inter-regional differences in
health care in Italy provides potential explanations for some
of the present findings. The challenge remains to ensure that
all menopausal women in Italy are properly informed about
VVA and have adequate access to the necessary health care
and treatments. Multivariate logistic regression of the above-
mentioned EU-SILC data showed that the odds of unmet
medical needs were significantly higher in women compared
to men [17]. The odds of unmet medical needs specifically
attributable to inaccessibility of health care (itself largely
due to the costs involved) were also higher in women. In
Tuscany (Central Italy), an ongoing collaboration involving
clinicians, HCPs, and policy-makers seeks to reduce geo-
graphic variation in health care that is not justified based
on the needs of patients [28]. Extension of this approach to
the macro-regional and national levels and its specific
application to VVA may be warranted.
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